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Chinese herbal medicine in the 
treatment of acute upper respiratory 
tract infection: a randomised, double 
blind, placebo-controlled clinical trial
Key Messages
1. Neither the duration nor 
severity of symptoms of upper 
respiratory tract infection 
was reduced after Traditional 
Chinese medicine treatment 
with either Jing Fan Bai Du san 
or Ying Qiao san. 
2. For patients with wind-cold 
syndrome, Jing Fan Bai Du san 
might be able to improve general 
health more than placebo.
3. Both Jing Fan Bai Du san 
and Ying Qiao san were well 
tolerated, with no excess in 
the incidence of side effects 
compared to placebo. 
4. Randomised double-blind 
placebo-controlled trials are 
objective methodology to 
determine the effectiveness and 
side effects of Chinese herbal 
medicines.
Hong Kong Med J 2009;15(Suppl 6):S30-4
Introduction
Acute upper respiratory tract infection (URTI) is the most common type of 
illness leading to consultation in primary care.1 There is no established cure 
for this ailment in western medicine. In Hong Kong, Chinese herbal medicine 
is commonly used for treating URTI, but research on its effectiveness or side 
effects is meagre. 
 The aim of this study was to determine whether treatment with Jing Fan 
Bai Du san and Ying Qiao san based on traditional Chinese medicine (TCM) 
diagnoses would significantly enhance the resolution (reduce the duration and/or 
severity of symptoms) and improve quality of life in patients with URTIs in 
primary care. 
Methods and subjects
This prospective randomised double-blind placebo-controlled trial was conducted 
from January 2006 to January 2007. It entailed 327 patients diagnosed with 
URTI in two government outpatient clinics in Hong Kong. Eligible patients were 
diagnosed by a registered Chinese medicine practitioner based on TCM and 
classified into wind-cold syndrome (n=162) and wind-heat syndrome (n=165). 
Patients in each group were randomised to receive concentrated TCM granules 
(Jing Fan Bai Du san for wind-cold syndrome and Ying Qiao san for wind-heat 
syndrome) or placebo for as long as the URTI symptoms persisted but up to a 
maximum of 10 days. 
 Patients recorded their symptoms and possible side effects in a diary for 21 
days, and were also followed up by telephone on days 0, 1, 4, 10, 14 and 20. On 
day 7, patients were assessed by the Chinese medicine practitioner for the URTI 
symptoms, side effects, and health-related quality of life (HRQOL) measured 
by the SF-36 health survey and Chinese Quality of Life (ChQoL) instrument. 
The diary and unused TCM were returned after 21 days, using a pre-paid postal 
envelope. Randomisation and follow-up rates of the subjects are shown in Fig 1. 
The drop out rate was low, ranging from 3% to 9%. 
 The TCM and placebo groups were similar in terms of age, sex and other 
socio-demographics (Table 1), as were the mean numbers of URTI contracted in 
previous year and the smoking history. The baseline HRQOL scores of TCM and 
placebo groups were not significantly different, except for general health scores 
of wind-cold syndrome group (44.86 vs 53.58).
Outcome measures and data analysis
The primary outcome measure was the proportion of patients with resolution 
of all URTI symptoms on days 4 and 7. Each symptom was scored 0 (if absent) 
or 1 (if present). Secondary outcome measures included the number of days 
to symptom resolution, change in total symptom score, the area under the 
curve of the total symptoms score, change in the SF36 and ChQoL scores, 
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number of sick-leave days, and the incidence of adverse 
effects. The difference in the proportion of patients with 
resolution of all URTI symptoms was tested separately in 
the wind-cold and wind-heat syndrome subgroups using 
Fisher’s exact test. The difference in proportion on day 7 
between the TCM and placebo groups was compared using 
logistic regression with adjustment for the use of western 
medicine. Sensitivity analyses were also performed. The 
area under the curve of the total symptom score over the 21 
days between the TCM and placebo groups were compared 
using regression analysis with and without adjustment for 
the use of western medicine. The change in individual and 
total symptom scores over time was compared between the 
two groups by the sign-rank tests. The incidence of side 
effects in the two groups were compared by Fisher’s exact 
test. All analyses were performed based on an intention-
to-treat basis. Missing values were replaced by the last 
observed value. 
Results
Symptoms resolution
The proportion of patients with symptom resolution was 
not significantly different between the TCM and placebo 
groups on days 1, 4, 7, 10, 14, 20 and 21, after adjusting 
for baseline values (Table 2). Around 50% of patients had 
symptoms resolved by day 7. More than 40% of patients had 
taken western medications (paracetamol, anti-histamines, 
soothing lozenges, and/or nasal decongestants), but the 
duration or severity of symptoms was not changed. No 
significant difference was found in the area under the curve 
of the total or individual symptom score in both the wind-
cold and wind-heat syndrome subgroups (Figs 2 and 3). 
Change in symptoms and health-related quality of 
life scores
There was no difference in the change in total or individual 
Fig 1. Patient randomisation and follow-up flow chart
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Parameters All patients Wind-cold syndrome Wind-heat syndrome
Traditional 
Chinese medicine
Placebo Jing Fan Bai 
Du san 
Placebo Ying Qiao san Placebo 
No. of patients 164 163 82 80 82 83
Mean±SD (range) age 
(years)
44.34±11.02 
(20-77)
43.20±11.48 
(18-74)
44.41±11.67 
(22-77)
42.04±11.46 
(20-73)
44.27±10.40 
(20-71)
44.33±11.45 
(18-74)
Female:male (%) 49:51 54:46 51:49 56:44 46:54 52:48
Mean (SD) symptom score
Total 26.90 (13.14) 27.29 (13.60) 26.63 (14.49) 27.14 (14.06) 27.18 (11.71) 27.43 (13.26)
Chills 0.76 (1.52) 0.83 (1.57) 0.72 (1.32) 0.96 (1.78) 0.81 (1.70) 0.71 (1.34)
Fever 1.17 (1.99) 0.82 (1.59) 1.04 (2.02) 0.65 (1.20) 1.31 (1.97) 0.97 (1.87)
Cough 2.74 (2.34) 2.71 (2.12) 2.91 (2.54) 2.58 (2.08) 2.58 (2.13) 2.82 (2.16)
Headache 2.31 (2.27) 2.81 (2.52) 2.23 (2.39) 2.73 (2.59) 2.38 (2.17) 2.87 (2.48)
Hoarseness 3.12 (2.45) 3.27 (2.41) 2.94 (2.56) 2.92 (2.27) 3.31 (2.33) 3.59 (2.50)
Muscle-ache 3.67 (2.64) 3.40 (2.50) 3.79 (2.55) 3.52 (2.56) 3.55 (2.73) 3.29 (2.47)
Running nose 2.50 (2.53) 2.66 (2.51) 2.63 (2.57) 3.18 (2.63) 2.37 (2.49) 2.19 (2.31)
Nasal obstruction 2.03 (2.30) 1.90 (2.39) 2.01 (2.42) 2.03 (2.54) 2.05 (2.19) 1.78 (2.25)
Itchy throat 3.34 (2.42) 3.35 (2.70) 3.59 (2.50) 3.39 (2.64) 3.09 (2.32) 3.30 (2.77)
Sore throat 3.76 (2.61) 3.76 (2.69) 3.09 (2.84) 3.01 (2.73) 4.42 (2.19) 4.43 (2.49)
Sneezing 1.49 (1.97) 1.79 (2.04) 1.68 (2.07) 2.17 (2.18) 1.31 (1.85) 1.46 (1.85)
Mean (SD) SF-36 health-
related quality of life score*
PCS 40.37 (8.18) 39.73 (9.23) 39.88 (7.69) 40.20 (9.73) 40.86 (8.66) 39.31 (8.79)
MCS 45.01 (11.41) 46.57 (10.26) 44.97 (11.97) 47.57 (11.66) 45.05 (10.90) 45.67 (8.80)
PF 87.21 (12.64) 85.60 (14.20) 88.40 (11.21) 85.00 (14.34) 86.03 (13.90) 86.14 (14.14)
RP 37.98 (35.07) 40.50 (36.48) 34.62 (33.28) 43.31 (35.34) 41.35 (36.67) 37.97 (37.52)
BP 57.97 (21.41) 56.84 (22.24) 57.10 (22.26) 58.73 (23.26) 58.83 (20.64) 55.14 (21.28)
GH 48.23 (19.20) 50.59 (19.40) 44.86 (19.58)† 53.58 (19.13)† 51.60 (18.32) 47.90 (19.37)
VT 43.33 (20.39) 43.67 (21.93) 43.40 (20.94) 46.83 (23.73) 43.27 (19.95) 40.82 (19.91)
SF 75.72 (25.37) 76.58 (23.09) 76.12 (26.13) 76.23 (25.89) 75.32 (24.75) 76.90 (20.42)
RE 49.57 (41.39) 51.78 (39.49) 48.29 (40.07) 54.46 (39.13) 50.85 (42.88) 49.37 (39.89)
MH 67.18 (19.22) 70.29 (17.12) 67.33 (20.85) 71.89 (18.13) 67.03 (17.57) 68.86 (16.14)
Mean (SD) Chinese quality 
of life score
Physical 56.10 (12.27) 56.66 (12.85) 55.94 (11.44) 57.45 (13.74) 56.26 (13.13) 55.95 (12.02)
Vitality and spirit 54.36 (15.04) 54.03 (14.33) 55.30 (15.41) 53.96 (14.87) 53.41 (14.71) 54.09 (13.92)
Emotion 78.51 (13.14) 80.47 (11.52) 78.89 (13.72) 80.96 (12.84) 78.13 (12.61) 80.03 (10.25)
Overall 62.99 (11.21) 63.72 (10.22) 63.38 (11.39) 64.13 (11.10) 62.60 (11.09) 63.36 (9.41)
Table 1. Baseline characteristics, symptoms, and health-related quality of life scores of patients
* PCS denotes physical component summary score, MCS mental component summary score, PF physical functioning, RP role limitation due to physical 
problems, BP bodily pain, GH general health, VT vitality, SF social functioning, RE role limitation due to emotional problems, and MH mental health
† P<0.05 by Monte Carlo exact test for likelihood-ratio Chi-square
symptom score between TCM and placebo groups at 
day 4, 7 or 21. After the adjustment for baseline values 
and western medicine use, patients receiving Jing Fan 
Bai Du san (in the wind-cold syndrome subgroup) had 
significantly greater improvement in the SF-36 general 
health scores at day 7 than those receiving placebo (Table 
3). No statistical significant difference was found in SF-36 
or ChQoL scores.
Adverse effects
One or more adverse effects were reported by 11% (placebo) 
and 11.25% (Jing Fan Bai Du san) patients in the wind-cold 
syndrome subgroup, and 20% (placebo) and 20.5% (Ying 
Qiao san) patients in the wind-heat syndrome subgroup. 
No significant difference was noted between the TCM and 
placebo groups in the incidence of adverse effects and the 
number of sick-leave days.
Table 2. Proportion of patients with resolution of symptoms
* By Fisher’s exact test
Day Wind-cold syndrome Wind-heat syndrome
Jing Fan Bai 
Du san (n=82)
Placebo 
(n=80)
P value* Risk 
difference
95% CI Ying Qiao 
san (n=82)
Placebo 
(n=83)
P value* Risk 
difference
95% CI
1 8.5% 6.3% 0.77 0.02 -0.06-0.10 3.7% 7.2% 0.50 -0.04 -0.11-0.03
4 35.4% 40.3% 0.62 -0.05 -0.50-0.10 26.6% 36.1% 0.24 -0.10 -0.24-0.05
7 51.2% 56.0% 0.63 -0.05 -0.20-0.11 49.4% 51.3% 0.87 -0.02 -0.17-0.14
10 67.9% 70.3% 0.86 -0.02 -0.17-0.12 67.9% 70.0% 0.86 -0.02 -0.17-0.12
14 82.5% 81.1% 0.84 0.01 -0.14-0.11 73.4% 82.5% 0.19 -0.09 -0.04-0.22
20 92.5% 83.8% 0.13 0.09 -0.19-0.02 89.7% 90.0% 1.00 0.00 -0.09-0.10
21 91.3% 91.8% 1.00 -0.01 -0.08-0.09 87.2% 83.8% 0.65 0.03 -0.14-0.08
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Fig 2. Comparison of total symptom scores in patients 
with wind-cold syndrome receiving Jing Fan Bai Du san or 
placebo
Fig 3. Comparison of total symptom scores in patients with 
wind-heat syndrome receiving Ying Qiao san or placebo
Parameters All patients Wind-cold syndrome Wind-heat syndrome
Traditional Chinese 
medicine
Placebo Jing Fan Bai Du 
san
Placebo Ying Qiao san Placebo
No. of patients 164 163 82 80 82 83
Mean (SD) change in 
symptom score
Total 2.32 (1.15) 2.35 (1.28) 2.30 (1.28) 2.36 (1.34) 2.34 (1.01) 2.34 (1.23)
Chills 0.73 (1.49) 0.82 (1.61) 0.68 (1.28) 0.96 (1.77) 0.79 (1.68) 0.69 (1.45)
Fever 1.13 (1.92) 0.78 (1.58) 1.05 (2.01) 0.63 (1.18) 1.22 (1.84) 0.91 (1.86)
Cough 2.49 (2.31) 2.41 (2.14) 2.74 (2.42) 2.38 (2.17) 2.24 (2.17) 2.43 (2.12)
Headache 2.13 (2.20) 2.67 (2.61) 2.09 (2.31) 2.63 (2.76) 2.18 (2.09) 2.71 (2.47)
Hoarseness 3.01 (2.43) 3.15 (2.42) 2.80 (2.54) 2.81 (2.31) 3.22 (2.31) 3.46 (2.48)
Muscle-ache 3.46 (2.56) 3.24 (2.44) 3.50 (2.48) 3.32 (2.45) 3.41 (2.66) 3.16 (2.44)
Running nose 2.32 (2.47) 2.52 (2.57) 2.46 (2.54) 3.01 (2.68) 2.17 (2.39) 2.08 (2.39)
Nasal obstruction 1.92 (2.27) 1.79 (2.45) 1.91 (2.41) 1.89 (2.56) 1.94 (2.13) 1.70 (2.36)
Itchy throat 3.18 (2.36) 3.20 (2.71) 3.41 (2.46) 3.32 (2.65) 2.95 (2.24) 3.09 (2.79)
Sore throat 3.68 (2.58) 3.58 (2.72) 3.01 (2.79) 2.95 (2.77) 4.37 (2.17) 4.16 (2.55)
Sneezing 1.43 (1.93) 1.67 (2.05) 1.61 (2.05) 2.04 (2.20) 1.24 (1.78) 1.33 (1.85)
Mean (SD) change in SF-36 
health-related quality of life 
score*
PCS 13.32 (8.44) 13.30 (9.45) 13.95 (7.85) 12.87 (9.57) 12.70 (8.99) 13.69 (9.39)
MCS 10.77 (11.91) 10.80 (10.35) 11.35 (12.77) 9.83 (11.80) 10.19 (11.04) 11.68 (8.81)
PF 11.19 (12.63) 11.69 (13.18) 10.58 (10.96) 12.29 (12.70) 11.79 (14.14) 11.14 (13.66)
RP 56.41 (37.12) 53.81 (39.55) 62.18 (35.75) 49.65 (40.13) 50.64 (37.79) 57.59 (38.89)
BP 32.11 (25.82) 34.23 (25.17) 31.60 (26.68) 32.79 (26.30) 32.62 (25.09) 35.53 (24.20)
GH 19.96 (18.39) 17.72 (19.10) 23.42 (19.53)† 16.08 (15.87)† 16.50 (16.60) 19.20 (21.63)
VT 30.67 (25.16) 31.03 (23.78) 32.24 (24.36) 27.78 (24.46) 29.10 (26.01) 33.99 (22.89)
SF 19.87 (26.02) 21.11 (23.68) 20.19 (28.08) 21.01 (26.02) 19.55 (23.97) 21.20 (21.50)
RE 41.45 (43.73) 45.03 (40.41) 44.02 (43.48) 43.52 (39.42) 38.89 (44.11) 46.41 (41.49)
MH 16.41 (19.01) 14.49 (16.65) 16.97 (20.14) 12.78 (18.17) 15.85 (17.93) 16.05 (15.07)
Mean (SD) change in 
Chinese quality of life score
Physical 6.69 (7.45) 7.88 (7.61) 6.43 (7.57) 7.98 (8.07) 6.96 (7.36) 7.79 (7.20)
Vitality and spirit 28.13 (18.04) 28.35 (17.56) 28.18 (19.20) 28.39 (16.87) 28.07 (16.93) 18.32 (18.27)
Emotion -0.45 (7.96) 0.97 (6.63) -0.53 (7.75) 0.56 (6.45) -0.37 (8.22) 1.35 (6.81)
Overall 9.49 (6.85) 10.52 (6.88) 9.38 (6.94) 10.40 (6.49) 9.60 (6.80) 10.63 (7.26)
Table 3. Change in symptom and quality of life scores of patients on day 7
* PCS denotes physical component summary score, MCS mental component summary score, PF physical functioning, RP role limitation due to physical 
problems, BP bodily pain, GH general health, VT vitality, SF social functioning, RE role limitation due to emotional problems, and MH mental health
† P<0.05 by sign-rank test
Discussion
This study adhered to guidelines of the consolidated 
standards for reporting trials. The numbers of patients in 
each subgroup were similar. Double-blind clinical trials 
based on TCM diagnoses were feasible. Over 90% of the 
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patients completed their treatment courses, suggesting good 
acceptance to clinical trials with TCM.
 This study did not reveal any significant benefit in terms 
of reducing the duration or severity of URTI symptoms 
after the treatment of Jing Fan Bai Du san (for wind-cold 
syndrome) or Ying Qiao san (for wind-heat syndrome). Other 
placebo-controlled trials have shown a benefit from these 
two TCMs in treating URTI.2-4 However, it is difficult to 
judge the validity of these trials because of methodological 
flaws such as problems with medication standardisation, 
randomisation, blinding, and analytic methods. A recently 
published randomised controlled trial also did not find any 
difference between Yin Qiao san and western medicine in 
resolving URTI symptoms.5 
 Jing Fan Bai Du san was associated with a significantly 
greater improvement in general health than placebo in the 
wind-cold syndrome subgroup. It might be able to improve 
general well-being although it could not alleviate specific 
URTI symptoms. An important objective of TCM is to improve 
the general well-being. This suggests that HRQOL might be an 
important outcome measure for TCM-treated patients. 
 Both TCM formulae were well tolerated with no serious 
adverse event reported by the patients. Although a higher 
percentage of wind-heat syndrome patients reported adverse 
effects, the events were mild and no different from those 
encountered on placebo treatment. Some of these adverse 
events might have been related to the URTI itself or to the 
western medicine use.
 Several factors could have affected the effectiveness 
of TCM. The TCM should be initiated at the onset of 
URTI symptoms, but most patients had already endured 
symptoms for more than 24 hours. We applied a more 
stringent criterion for the diagnosis of URTI, compared to 
trials that showed positive results included all patients with 
any subjective symptoms. The TCM formulae were given 
as minimum doses. Further studies with larger dosages 
should be performed.
  
Conclusions
No effect on URTI symptom resolution or reduction was 
demonstrated after treatment with Jing Fan Bai Du san 
or Ying Qiao san. Nonetheless, in patients with wind-cold 
syndrome. Jing Fan Bai Du san might be able to improve 
general health more than placebo. Both TCM formulae were 
well tolerated, and there was no difference in the incidence 
of side effects compared to placebo. 
 Randomised double-blind placebo-controlled trials 
can be used to determine the effectiveness and side effects 
of TCM treatments. It is the recommended research 
methodology to obtain objective evidence on the usefulness 
of TCM treatments.
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